A pproximately six years ago, the Japanese Society of Nuclear Cardiology (JSNC) launched its official journal, the Annals of Nuclear Cardiology (ANC), with the ultimate goal of advancing research and clinical practice by those in the field of nuclear cardiology, including physicians, technologists, and scientists, as well as the industries that support them. Initially JSNC aimed to promote its own members’ research and clinical practice and therefore it required any non-JSNC members who wanted to submit their manuscript to ANC to become JSNC members. However, as ANC has become bettter known among physicians and researchers on different continents and as the nature of research itself has moved further towards examining issues on a global scale, the time has come to open ANC not only to our members but to all nuclear cardiology researchers around the world. Beginning this year, ANC therefore no longer requires authors to become JSNC members or to pay a submission fee. With this change, ANC is now more accessible to everyone in the nuclear cardiology field around the world. In this spirit, the editorial board of ANC is working to ensure that articles published in ANC can be accessed via major search engines. Board members have been working very hard to collect the information necessary to apply to such search engines, but further steps are necessary. First, ANC needs to have a more international perspective. Therefore, the ANC editorial board is looking to include international advisory members among its ranks. This move will be coming soon. We are planning to apply to PubMed or PubMed Central operated by the National Institute of Health in the United States. Improving the quality of original articles and technical articles is now even more important and so last year we started an editorial support program. Through this program, editorial board members work with authors preparing manuscripts for submission. Beginning with this edition of ANC, original articles accepted for publication will have undergone thorough scientific editing as part of ANC’s process to support authors in manuscript preparation and to improve the overall quality of manuscripts. Authors sometimes overlook the new insight their studies may provide. In this regard, editorial board members, who have great depth of experience, will endeavour to help these authors to identify such new insights from their work. For this issue of ANC at least, the number of original articles is still limited. However, I expect this number to grow in the coming years. Along with increasing the quantity of manuscripts, we continuously aim to improve their quality. In this regard, the review process is very important. Therefore, I have asked experienced reviewers in Asia, the UK, Europe, North America, and South America to review articles submitted to ANC. Among ANC reviewers this year are a number of core American Society of Nuclear Cardiology members. I am especially grateful to those who have been wil
{"title":"ANC Opens up to the World","authors":"K. Yoshinaga","doi":"10.17996/anc.20-00001","DOIUrl":"https://doi.org/10.17996/anc.20-00001","url":null,"abstract":"A pproximately six years ago, the Japanese Society of Nuclear Cardiology (JSNC) launched its official journal, the Annals of Nuclear Cardiology (ANC), with the ultimate goal of advancing research and clinical practice by those in the field of nuclear cardiology, including physicians, technologists, and scientists, as well as the industries that support them. Initially JSNC aimed to promote its own members’ research and clinical practice and therefore it required any non-JSNC members who wanted to submit their manuscript to ANC to become JSNC members. However, as ANC has become bettter known among physicians and researchers on different continents and as the nature of research itself has moved further towards examining issues on a global scale, the time has come to open ANC not only to our members but to all nuclear cardiology researchers around the world. Beginning this year, ANC therefore no longer requires authors to become JSNC members or to pay a submission fee. With this change, ANC is now more accessible to everyone in the nuclear cardiology field around the world. In this spirit, the editorial board of ANC is working to ensure that articles published in ANC can be accessed via major search engines. Board members have been working very hard to collect the information necessary to apply to such search engines, but further steps are necessary. First, ANC needs to have a more international perspective. Therefore, the ANC editorial board is looking to include international advisory members among its ranks. This move will be coming soon. We are planning to apply to PubMed or PubMed Central operated by the National Institute of Health in the United States. Improving the quality of original articles and technical articles is now even more important and so last year we started an editorial support program. Through this program, editorial board members work with authors preparing manuscripts for submission. Beginning with this edition of ANC, original articles accepted for publication will have undergone thorough scientific editing as part of ANC’s process to support authors in manuscript preparation and to improve the overall quality of manuscripts. Authors sometimes overlook the new insight their studies may provide. In this regard, editorial board members, who have great depth of experience, will endeavour to help these authors to identify such new insights from their work. For this issue of ANC at least, the number of original articles is still limited. However, I expect this number to grow in the coming years. Along with increasing the quantity of manuscripts, we continuously aim to improve their quality. In this regard, the review process is very important. Therefore, I have asked experienced reviewers in Asia, the UK, Europe, North America, and South America to review articles submitted to ANC. Among ANC reviewers this year are a number of core American Society of Nuclear Cardiology members. I am especially grateful to those who have been wil","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73166847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Triglyceride deposit cardiomyovasculopathy (TGCV) is a newly identified disease that was discovered in individuals who required cardiac transplantation in Japan in 2008. Defective intracellular lipolysis causes triglyceride (TG) accumulation in the myocardium and coronary artery vascular smooth muscle cells, which results in severe heart failure and coronary artery disease with poor prognosis. A known cause of TGCV is a genetic deficiency of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in the intracellular hydrolysis of TG. TGCV is classified into primary TGCV with ATGL mutations and idiopathic TGCV without ATGL mutations. Since its discovery, the Japan TGCV Study Group has attempted to elucidate its pathophysiology, develop diagnostic procedures, and specific treatment. Myocardial scintigraphy with iodine-123-β-methyl iodophenyl-pentadecanoic acid (123I-BMIPP) is a unique imaging modality for evaluating myocardial lipolysis in vivo. The washout rate of 123I-BMIPP is an essential indicator for the diagnosis of TGCV. Along with our efforts to provide awareness of and insights into this disease concept, we found that the cumulative number of clinically diagnosed patients has reached >200 and the cases are distributed throughout Japan. In addition, we successfully completed three investigator-initiated clinical trials of a potential therapeutic agent (CNT-01) for TGCV, which was assigned by the Ministry of Health, Labour, and Welfare, Japan, under the SAKIGAKE Designation System in June 2020. Here, we provide the Diagnostic Criteria 2020 for TGCV in order to further promote this "rare and intractable disease" project.
{"title":"The Diagnostic Criteria 2020 for Triglyceride Deposit Cardiomyovasculopathy.","authors":"Kunihisa Kobayashi, Yasuhiko Sakata, Hideyuki Miyauchi, Yoshihiko Ikeda, Yasuyuki Nagasawa, Kenichi Nakajima, Kazunori Shimada, Junji Kozawa, Hiroyuki Hao, Tetsuya Amano, Hiroshi Yoshida, Tohru Inaba, Chikako Hashimoto, Ken-Ichi Hirano","doi":"10.17996/anc.20-00131","DOIUrl":"10.17996/anc.20-00131","url":null,"abstract":"<p><p>Triglyceride deposit cardiomyovasculopathy (TGCV) is a newly identified disease that was discovered in individuals who required cardiac transplantation in Japan in 2008. Defective intracellular lipolysis causes triglyceride (TG) accumulation in the myocardium and coronary artery vascular smooth muscle cells, which results in severe heart failure and coronary artery disease with poor prognosis. A known cause of TGCV is a genetic deficiency of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in the intracellular hydrolysis of TG. TGCV is classified into primary TGCV with ATGL mutations and idiopathic TGCV without ATGL mutations. Since its discovery, the Japan TGCV Study Group has attempted to elucidate its pathophysiology, develop diagnostic procedures, and specific treatment. Myocardial scintigraphy with iodine-123-<i>β</i>-methyl iodophenyl-pentadecanoic acid (<sup>123</sup>I-BMIPP) is a unique imaging modality for evaluating myocardial lipolysis <i>in vivo.</i> The washout rate of <sup>123</sup>I-BMIPP is an essential indicator for the diagnosis of TGCV. Along with our efforts to provide awareness of and insights into this disease concept, we found that the cumulative number of clinically diagnosed patients has reached >200 and the cases are distributed throughout Japan. In addition, we successfully completed three investigator-initiated clinical trials of a potential therapeutic agent (CNT-01) for TGCV, which was assigned by the Ministry of Health, Labour, and Welfare, Japan, under the SAKIGAKE Designation System in June 2020. Here, we provide the Diagnostic Criteria 2020 for TGCV in order to further promote this \"rare and intractable disease\" project.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"6 1","pages":"99-104"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133930/pdf/anc-6-99.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Murata, T. Toyama, S. Kasama, H. Hoshizaki, M. Kurabayashi
Background : Myocardial perfusion imaging (MPI) by single photon emission computed tomography is widely performed in patients with coronary artery disease (CAD). These days, the relation between MPI findings and the prognosis of CAD has been reported. Methods : A total of 188 consecutive patients with stable CAD were retrospectively enrolled. They all had ischemic findings in the initial stress/resting MPI and underwent a repeat stress/resting MPI within one year of the initial test. We evaluated the summed stress score, summed rest score, and summed difference score (SDS). We defined %residual ischemia as the percent SDS on repeat MPI relative to that on initial MPI (post SDS × 100/pre SDS). We followed the patients until occurrence of an adverse event or for at least one year after repeat MPI to assess adverse events including cardiac death, nonfatal myocardial infarction, hospitalization for heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, stroke, and non-cardiac death. Results : Fifty-four patients (28.7%) experienced adverse events. According to multivariate Cox proportional hazards regression analysis of adverse event rates, more extensive %residual ischemia was associated with a higher incidence of adverse events (HR 1.025, p = 0.018). According to Kaplan-Meier analysis, patients with significant %residual ischemia had a higher risk of adverse events than those with mild %residual ischemia (p = 0.001, log rank test). Conclusion : In patients with CAD, significant residual ischemia on repeat MPI may predict a worse prognosis for CAD patients receiving optimal medical therapy with or without coronary revascularization.
{"title":"Significant Residual Ischemia on Myocardial Perfusion Imaging after Optimal Medical Therapy with or without Coronary Revascularization Predicts a Worse Prognosis","authors":"T. Murata, T. Toyama, S. Kasama, H. Hoshizaki, M. Kurabayashi","doi":"10.17996/ANC.19-00086","DOIUrl":"https://doi.org/10.17996/ANC.19-00086","url":null,"abstract":"Background : Myocardial perfusion imaging (MPI) by single photon emission computed tomography is widely performed in patients with coronary artery disease (CAD). These days, the relation between MPI findings and the prognosis of CAD has been reported. Methods : A total of 188 consecutive patients with stable CAD were retrospectively enrolled. They all had ischemic findings in the initial stress/resting MPI and underwent a repeat stress/resting MPI within one year of the initial test. We evaluated the summed stress score, summed rest score, and summed difference score (SDS). We defined %residual ischemia as the percent SDS on repeat MPI relative to that on initial MPI (post SDS × 100/pre SDS). We followed the patients until occurrence of an adverse event or for at least one year after repeat MPI to assess adverse events including cardiac death, nonfatal myocardial infarction, hospitalization for heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, stroke, and non-cardiac death. Results : Fifty-four patients (28.7%) experienced adverse events. According to multivariate Cox proportional hazards regression analysis of adverse event rates, more extensive %residual ischemia was associated with a higher incidence of adverse events (HR 1.025, p = 0.018). According to Kaplan-Meier analysis, patients with significant %residual ischemia had a higher risk of adverse events than those with mild %residual ischemia (p = 0.001, log rank test). Conclusion : In patients with CAD, significant residual ischemia on repeat MPI may predict a worse prognosis for CAD patients receiving optimal medical therapy with or without coronary revascularization.","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82280137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Hirano, M. Higashi, Hideyuki Miyauchi, A. Takagi, Y. Ikeda, Y. Nakano, T. Amano
{"title":"Increased Washout of 123I-BMIPP in Triglyceride Deposit Cardiomyovasculopathy (TGCV) with Severe Coronary Stenosis","authors":"K. Hirano, M. Higashi, Hideyuki Miyauchi, A. Takagi, Y. Ikeda, Y. Nakano, T. Amano","doi":"10.17996/anc.19-00106","DOIUrl":"https://doi.org/10.17996/anc.19-00106","url":null,"abstract":"","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76616700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Interpreting medical scans acquired with nuclear imaging equipment requires testing the equipment to assure that the best results achievable are routinely and reliably produced. Strict adherence to predetermined schedules for testing and recording the results for gamma cameras will facilitate the efficient operation of a Nuclear Cardiology laboratory, satisfy regulatory and accreditation requirements, and instill confidence in the readings obtained by interpreting the collected patient scans, for the ultimate benefit of the patients being evaluated.
{"title":"Gamma Camera Testing Schedules for Nuclear Cardiology Facilities","authors":"K. Nichols, A. Tosh","doi":"10.17996/anc.19-00104","DOIUrl":"https://doi.org/10.17996/anc.19-00104","url":null,"abstract":"Interpreting medical scans acquired with nuclear imaging equipment requires testing the equipment to assure that the best results achievable are routinely and reliably produced. Strict adherence to predetermined schedules for testing and recording the results for gamma cameras will facilitate the efficient operation of a Nuclear Cardiology laboratory, satisfy regulatory and accreditation requirements, and instill confidence in the readings obtained by interpreting the collected patient scans, for the ultimate benefit of the patients being evaluated.","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81899221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I n this issue of the Annals of Nuclear Cardiology, there are two review articles related to myocardial blood flow assessment (MBF; ml/g-myocardium/min). One is using dynamic perfusion CT by Manabe et al., and the other is using dynamic perfusion MR by Ichikawa et al. (1, 2). MBF measurement has been mainly performed by dynamic positron emission tomography (PET) imaging with 13 N-NH3, 15 O-H2O, and 82 Rb (3, 4). PET MBF assessment is a gold standard for non-invasive quantification of MBF, however, there are limited number of facilities where dynamic perfusion PET can be available in the clinical settings. Recently, there are trials to quantify MBF using semi-conductor detector single photon emission computed tomography (SPECT) (5) and the PET MBF quantification methodology using 99m Tc-MIBI, 99m Tctetrofosmin or 201 Tl-TlCl. In addition to the limited number of facilities where semi-conductor or high sensitivity SPECT systems are installed, there are limitations of SPECT MBF quantification such as underestimation and accuracy when using 99m Tc-agents, and low counts or noisy data. If non-invasive MBF assessment is available with widely used modalities such as CT and MR, it would be of beneficial for many coronary artery disease (CAD) patients in the clinical setting.
{"title":"Current Status of Myocardial Blood Flow Quantification by CT and MR","authors":"T. Mochizuki","doi":"10.17996/anc.19-00109","DOIUrl":"https://doi.org/10.17996/anc.19-00109","url":null,"abstract":"I n this issue of the Annals of Nuclear Cardiology, there are two review articles related to myocardial blood flow assessment (MBF; ml/g-myocardium/min). One is using dynamic perfusion CT by Manabe et al., and the other is using dynamic perfusion MR by Ichikawa et al. (1, 2). MBF measurement has been mainly performed by dynamic positron emission tomography (PET) imaging with 13 N-NH3, 15 O-H2O, and 82 Rb (3, 4). PET MBF assessment is a gold standard for non-invasive quantification of MBF, however, there are limited number of facilities where dynamic perfusion PET can be available in the clinical settings. Recently, there are trials to quantify MBF using semi-conductor detector single photon emission computed tomography (SPECT) (5) and the PET MBF quantification methodology using 99m Tc-MIBI, 99m Tctetrofosmin or 201 Tl-TlCl. In addition to the limited number of facilities where semi-conductor or high sensitivity SPECT systems are installed, there are limitations of SPECT MBF quantification such as underestimation and accuracy when using 99m Tc-agents, and low counts or noisy data. If non-invasive MBF assessment is available with widely used modalities such as CT and MR, it would be of beneficial for many coronary artery disease (CAD) patients in the clinical setting.","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80631110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Editor-in Chief of the Journal of Nuclear Cardiology created in 2014 the “Mentorship at Distance Committee” to provide editorial assistance to foreign authors. The chair of the committee discusses in the present communication his 3-year experience with mentoring manuscripts. He addresses the selection of manuscripts, the process of mentoring and common problems encountered and resolved. The mentoring process required the full commitment by both the mentor and the author, because of necessary intensive and frequent communications by email. The average time involved from start to finish averaged about 9 weeks. Eight of 11 mentored manuscripts could be sufficiently revised and were accepted for publication. ・
{"title":"Medical Writing by Non-native English-speaking Authors","authors":"F. Wackers","doi":"10.17996/ANC.19-00095","DOIUrl":"https://doi.org/10.17996/ANC.19-00095","url":null,"abstract":"The Editor-in Chief of the Journal of Nuclear Cardiology created in 2014 the “Mentorship at Distance Committee” to provide editorial assistance to foreign authors. The chair of the committee discusses in the present communication his 3-year experience with mentoring manuscripts. He addresses the selection of manuscripts, the process of mentoring and common problems encountered and resolved. The mentoring process required the full commitment by both the mentor and the author, because of necessary intensive and frequent communications by email. The average time involved from start to finish averaged about 9 weeks. Eight of 11 mentored manuscripts could be sufficiently revised and were accepted for publication. ・","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89665868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"JSNC 2020 in Aichi","authors":"J. Hashimoto","doi":"10.17996/anc.19-002","DOIUrl":"https://doi.org/10.17996/anc.19-002","url":null,"abstract":"","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85879348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rubidium-82 is the most well-established cardiac PET flow tracer with over 6 decades of literature. Due to its robust supply, short physical half-life, ease of use, low radiation dose and favorable kinetics it can deliver comprehensive clinical information with minimal risk and maximum convenience to patients and clinical staff. Optimized 82 Rb protocols can deliver high quality myocardial perfusion imaging, functional cardiac images and absolute myocardial blood flow and flow reserve from a single session 30 minutes clinical protocol‒benefiting patient convenience and clinical throughput. In a high volume setting the cost of 82 Rb PET can be dramatically lower than that of alternative PET flow tracers. These factors compound toward 82 Rb as the best PET flow tracer for high-throughput clinics.
{"title":"82Rb is the Best Flow Tracer for High-volume Sites","authors":"R. Klein, R. deKemp","doi":"10.17996/anc.19-00105","DOIUrl":"https://doi.org/10.17996/anc.19-00105","url":null,"abstract":"Rubidium-82 is the most well-established cardiac PET flow tracer with over 6 decades of literature. Due to its robust supply, short physical half-life, ease of use, low radiation dose and favorable kinetics it can deliver comprehensive clinical information with minimal risk and maximum convenience to patients and clinical staff. Optimized 82 Rb protocols can deliver high quality myocardial perfusion imaging, functional cardiac images and absolute myocardial blood flow and flow reserve from a single session 30 minutes clinical protocol‒benefiting patient convenience and clinical throughput. In a high volume setting the cost of 82 Rb PET can be dramatically lower than that of alternative PET flow tracers. These factors compound toward 82 Rb as the best PET flow tracer for high-throughput clinics.","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76015160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：